CVM CEL-SCI Corp.: Book Value per Share

The book value per share chart for CEL-SCI Corporation (CVM) on GURU.Markets illustrates capital dynamics, where 0.62 shows the current value of the metric. Biosynthesis stability is ensured by a proprietary plant in Maryland featuring redundant ventilation. The robotization of bioreactors in clean zones minimizes errors, accelerating the market launch of Multikine. Growth prospects for CEL-SCI Corporation (CVM) depend on FDA approval and a unique immune activation mechanism.

CVM (CEL-SCI Corporation) Book Value per Share history from 07/04/2022 to 10/29/2026

CVM (CEL-SCI Corp.): analytical breakdowns and indicator data

- current quotes and average value forecast:

Price Chart CEL-SCI Corp|CVM - Consensus Target

- company stock capitalization data:

Market Capitalization CEL-SCI Corporation|CVM - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share CEL-SCI|CVM - Book Capitalization|Market Value to Book Value Ratio cel-sci.com|CVM - Total Business Assets

- debt and liquidity data:

Basic company analysis:CVM - cel-sci.com

Investors utilize multiples to verify the issuer's financial stability by assessing the real value of net assets per share. Analyzing this book value assessment allows for tracking the capital dynamics of CEL-SCI Corporation (CVM), which is critically important for the biotechnology sector, where significant pricing power following the approval of Multikine and inelastic patient demand provide fundamental potential for asset value growth.

Competing companies

ONC - Net Assets per Single Share|Halozyme Corp (HALO) - Accounting Value per Share|RVMD: Book Value per Share|Accounting Value per Share ascentage.com|CGON (CG Oncology) - Book Value per Share|Book Value per Share UroGen Pharma Ltd|Net Assets per Single Share Bicara Bio (BCAX)|Personalis Genomics - Equity per Share|Book Value per Share ERAS (Erasca, Inc.)|DCTH - Accounting Value per Share|Y-mAbs Therapeutics, Inc. - Book Value per Share|Net Asset Value per Share Aura Biosciences Inc|candeltx.com (CADL) - Net Assets per Single Share|Accuray, Inc. - Accounting Value of a Share|Accounting Value per Share SLS|ACTU: Accounting Value of a Share|Book Value per Share CTOR|Accounting Value per Share tuhurabio.com HURA|Protara - Accounting Value per Share|Book Value per Share Fate Pharma FATE|WHWK - Net Assets per Single Share|Accounting Value of a Share TCRX (TScan Therapeutics)|CSBR: Book Value per Share|Net Asset Value per Share XBiotech (XBIT)|OSTX (OS Therapies Inc) - Book Value per Share|Accounting Value per Share radiopharmtheranostics.com (RADX)|Book Value per Share ARTV|ANL - Net Asset Value per Share|Net Assets per Single Share Veru VERU|Tempest Therapeutics Inc - Net Assets per Single Share|XLO: Accounting Value per Share|Book Value of One Share Renovaro Inc. (RENB)|muraloncology.com (MURA) - Net Assets per Single Share|KAPA - Net Assets per Share|OKUR (OnKure Therapeutics, Inc.) - Book Value per Share|Accounting Value per Share CytoMed (GDTC)|Book Value per Share CRIS|Net Assets per Share apollomicsinc.com|Tharimmune, Inc. - Accounting Value per Share|Accounting Value of a Share ADVB|Genprex - Book Value per Share|Calidi Biotherapeutics (CLDI) - Accounting Value per Share|Sunshine Biopharma, Inc. (SBFM) - Net Assets per Single Share|Net Asset Value per Share Xenetic Biosciences, Inc. (XBIO)|Net Assets per Single Share Salarius Pharmaceuticals|PPBT: Accounting Value of a Share|Net Assets per Single Share American Oncology Network (AONC)|BGNE: Share Book Value|Net Assets per Single Share Checkpoint Therapeutics, Inc CKPT|elevationoncology.com (ELEV) - Net Asset Value per Share|ICAD - Net Assets per Single Share|Accounting Value of a Share IKNA (Ikena Oncology, Inc.)|NTBL: Book Value per Share|Viracta Therapeutics, Inc. (VIRX) - Book Value per Share|Accounting Value per Share MOR|NAYA (NAYA Biosciences Corp) - Book Price of a Share|Book Value per Share AAPGV